SLC5A2 and type 2 diabetes mellitus: Consistent with our research findings, in Otagaki et al.‘s study, the SGLT-2 inhibitor tofogliflozin significantly improved LVEF in patients with type 2 diabetes (5.0 ± 6.9% vs. -0.6 ± 5.5%, P = 0.006) [21].